Clinical Study On Antioxidative Effect Of Rubigin And Its Effect On Endothelial Function In Patients With Primary Hypertension Or Coronary Heart Disease

lObjectivelAtheroscIerosis is an inflammatory disease. Because high plasma concentrationsof Iipoprotein(LDL) cholesteroI, are one of the principal risk lhctors fOratherosclerosis,the process of atherogenesis has been considered by many to cOnsistlargely of the accumulation of 1ipids witl1in the artery wall,however,it is l11ucl1 morethan that. In fact,the Iesions of atherosclerosis represent a series of highly specificcellular and molecular responses that can best be described,in aggregate,as aninflammatory disease. We investgated antioxidantive effect of rubigin and its ef1bcton vascular endothial function and plasma Iipids in patients with essentialhypertension or coronary heart disease al1d try to provide a new cIue fOr the treatme11tof atheroscIerotic cardiovascular diseases.lMaterial and Methodsll. Patients and division:to Patients with essential hypertension(EH): l degree or lI degree. (according tothe standard of the WHO/lSH classification in l999, l degree hypertensio11 is(SBP) l40 to l59 mmHg and (or) (DBP) 90 to 99mmHg (l mmlJg=0.l33kPa).and SBP l60 to l79 mmHg and (or) DBP l00 to l09mmHg belo11g to Il degreehypertension.). and patients with coronary heart disease(CHD) oId myocardialinfarction, silent myocardial ischemia or stab1e angina pectoris whose exercise test ispositive or coronary arteriongraphy proved that at least One of coronary arteriesdiametCr is decreased more than seventy-five percent.@ Division: l07 patients(aged 32 to 85) with EH or CHD were randomlydivided into three groups: Rubigin group(38 cases,2l maIes,l7 females),VitEgroup(34 cases,16 males,l8 females) and pacebo group(35 cases,20 males,l5females).2. Testing drug and Method of taking drug:ro Drugs:Testing drug: kubigin 375mg/ pellct, provided by Americal1 CAPSULES works.Contrast drug: VitE, 100mg/pellet.PIacebo: produced the same form, colour and size just as the testing drug andcontained escipient.@ Method of taking drug:All patients to be seIected sl1ould stop drinking tea or otl1er beverages related totea and taking drugs or other ones affecting the test two week before the test, and tryto decrease the intake of food wl1ich have strong oxidation such as lish and l11eat.After entering the test period, they would be assigned to receivc rubigin (l pe1let perday), VitE (I pellet per day) or pIacebo (l pellet per day) after breakfast. Tl1e testlasted 8-week period.3. Plasm TAC,ox-LDL, vWF al1d erytl1rocyte SOD were determined using reagentkits.lResultsll.The effect of Rubigin or VitE on plasma TAC,oxLDL,vWF and eryt11rocyteSOD activity in patients with EH or CHDCompared with baseline, plasma TAC and erythrocyte SOD activity in patientswith EH or CHD increased at 4 weeks aftcr taking rubigi11 or VitEty,<0.05). Forpatients taking rubigin, tl1ere was a significant increase in pIasma TAC anderythrocyte SOD activity at 8 weeks (P<0.0l). Patients on rubigin showed astatistically decrease in plasma oxLDL and vWF after 4 weeks of treatment(P<0.05),followed by a remarkable reduction at l2 weeks(P<0.0I). However, Patientsreceiving VitE showed no significant changes in plasma TAC,oxLDL,vWF anderythrocyte SOO activity after 8 weeks of treatment compared witl1 week 4. PIasmaoxLDL and vWF in rubigin group were lower than that in placebo group. There wereno significant changes in TAC a11d SOD baseline among rubigil1 group,VitE groupand placebo group.2.The effect of Rubigin or VitE on plasma lipids in patients with EIl or CIlOFor patients taking VitE or placebo, there were no statistically significantchanges in plasma lipids at 4,8weeks comparcd with baseIine. Patients on rubiginshowed a statistically significant fall in plasma TC and no statistica[ly remarkablechange in plasma TG,LDL-C and HDL-C after l2 weeks of treatment compared withbefOre taking rubigin.[Conclusionsll. For patients with EH or CHD, plasma TAC and erythrocyte SOD activity werelower than that i...